VAM
CBAY

Visium Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Visium Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-321,158
Closed -$543K – 668
2015
Q4 		$543K Hold
321,158
– – 0.01% 487
2015
Q3 		$623K Sell
321,158
-229,790
-42% -$626K 0.01% 547
2015
Q2 		$1.48M Sell
550,948
-202,843
-27% -$833K 0.02% 469
2015
Q1 		$5.22M Buy
753,791
+414,735
+122% +$3.98M 0.08% 254
2014
Q4 		$3.33M Buy
+339,056
New +$2.73M 0.05% 339

Other funds holding CBAY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Visium Asset Management's CBAY Position: Q1 2016 in Review

Visium Asset Management sold out of Cymabay Therapeutics (CBAY) in Q1 2016, closing a stake of 321,158 shares — an estimated $543K sold.

Visium Asset Management first reported a position in CBAY in Q4 2014 and held it in 5 quarters. The position peaked at $5.22M in Q1 2015. 30 funds tracked by Wall St. Rank hold CBAY as of Q1 2016.

  • Visium Asset Management reported no remaining Cymabay Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Visium Asset Management sold 321,158 Cymabay Therapeutics shares in Q1 2016, an estimated $543K.
  • Visium Asset Management first reported a position in Cymabay Therapeutics in Q4 2014 and held it in 5 quarters.
  • Visium Asset Management's Cymabay Therapeutics position peaked at $5.22M in Q1 2015.
  • 30 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2016.

Based on Visium Asset Management's 13F filing for Q1 2016, filed 16 May 2016.